(R)-Hexahydro-difenidol has a higher affinity for M 1 receptors in NB-OK 1 cells, pancreas M 3 and striatum M 4 receptors (pKi 7.9 to 8.3) than for cardiac M 2 receptors (pKi 7 .0). (8)-Hexahydro-difenidol, by contrast, is nonselective (pKi 5.8 to 6.1). Our goal in the present study was to evaluate the importance ofthe hydrophobic phenyl, and cyclohexyl rings of hexahydro-difenidol for the stereoselectivity and reeeptor selectivity of hexahydro-difenidol binding to the four muscarinic receptors. Our results indieated that replacement of the phenyl ring of hexahydro-difenidol by a cyclohexyl group <~ dicyclidol) and ofthe cyclohexyl ring by a phenyl moiety <~ difenidol) indueed a !arge (4-to 80-fold) decrease in binding affinity for all musearlnie receptors. Difenidol had a signifieant preference for M 1 , M 3 , and M 4 over M 2 receptors; dicyclidol, by eontrast, had a greater affinity for M 1 and M 4 than for M 2 and M 3 receptors. The binding free energy deerease due to replacement ofthe phenyl and the cyelohexyl groups of(R)-hexahydro-difenidol by, respectively, a eyclohexyl and a phenyl moiety was almostadditive in the ease of M 4 (striatum) binding sites. In the ease ofthe cardiac M 2 , pancreatic M 3 , or NB-OK 1 M 1 receptors the respective binding free energies were not eompletely additive. These results suggest that the four (R)-hexahydro-difenidol ''binding moieties" (phenyl, cyclohexyl, hydroxy, and protonated amino group) cannot simultaneously form optimal interaetions with the M 1 , M 2 , and M 3 muscarinic receptors. When eaeh of the hydrophobic groups is modified, the position of the whole molecule, relative to the four subsites, was changed to allow an optimal overall interaction with the musearlnie receptor.
INTRODUCTION
At least three pharmacologically and structurally distinct muscarinic receptors eoexist in mammalian tissues. 1 • 2 M 1 receptors, with a high affinity for pirenzepine, are typically found in neuronal tissues. 3 These receptors have a low affinity for AF-DX 116 (11-( { (2-[ ( diethy lamino )methy l]-1-pi peridiny I }acety D-5-11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one) and a high affinity for 4-DAMP (4-diphenylacetoxy-N-methylpiperidine methiodide) and hexahydro-sila-difenidol.
-
6 M 2 receptors, with a low affinity for pirenzepine and a high affinity for AF-DX 116, are typical of eardiac tissues. 7 They show a .low affini ty for 4-DAMP and hexahydro-sll adifenidol."-6·8·9 M 3 receptors have low affinities for pirenzepine and AF-DX 116, and high affinities for 4-DAMP10 and hexahydro-sila-difenidol. 5 • 6 · 9 They are typically detected in secretory glands 11 • 12 and in smooth muscle. 1 • 2 • 9 There is a candidate M 4 receptor found in rat striatum (previously called "B" sites) which differs from M 3 receptors by its high affinity for himbacine and methoctramine. 13 Hexahydro-difenidol ( Fig. 1) is weil characterized as ileum-preferring musearlnie antagonist (high affinity for M 3 greater affinity than M 2 receptors.
Wehave already demonstrated that muscarinic receptors are capable of discriminating the two enantiomers of hexahydrodifenidol, and have a greater affinity for the (R)-enantiomer.
•
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In a previous study on the stereoselective binding of procyclidine enantiomers, we suggested that muscarinic receptor subtypes possess four binding subsites for antagonists. 15 One of these "subsites" is the ionic binding site recognizing the protonated amino group of procyclidine; the second, a polar site forming a hydrogen bond with the procyclidine hydroxy group, and the two hydrophobic binding sites recognizing, respectively, the phenyl or the cyclohexyl groups of (R)-procyclidine with a greater affinity. Our results further indicated that when (8)-procyclidine is brought into contact with the receptor, the ionic and hydroxy groups are in the correct position, and the phenyl and the cyclohexyl groups in contact, respectively, with the cyclohexylpreferring and phenyl-preferring subsites. 15 Given the great structure homology of procyclidine and hexahydro-difenidol, we expected that the procyclidine binding model should also be applicable to hexahydro-difenidol (Fig. 2) . To test this hypothesis, we decided to measure the affinity of two achiral compounds structurally related to hexahydro-difenidol: difenidol (containing an additional phenyl moiety instead of the cyclohexyl group) (Fig. 1) and dicyclidol (containing an additional cyclohexyl moiety instead of the phenyl group). We hoped to measure the difference of binding energy of a phenyl versus cyclohexyl group with each hydrophobic subsite. grade available. All antagonists tested were synthesized in our laboratories. The hexahydro-difenidol enantiomers were prepared as previously published, 16 difenidol was synthesized according to the literature, 17 and dicyclidol was obtained by analogy to the synthesis of (R)-and (8)-hexahydro-difenidol 16 starting from dicyclohexyl ketone (unpublished results). The enantiomeric excess (ee) of (R)-and (S)-hexahydro-difenidol was >99.8%, determined by calorimetric analysis. 16 
MATERIALS AND METHODS Drugs
Homogenate Preparations
Human NB-OK 1 neuroblastoma cells were cultured in RPMI 1640 medium enriched with 10% foetal calf serum, 100 units/ml penicillin, and 100 ~g/ml streptomycin. To prepare rat tissue homogenates, male Wistar albino rats (200-250 g) were killed by decapitation and the heart, pancreas, and striatum immediately removed. Homogenate preparations were perfonned at 4°C. The heart was rinsed in isotonic NaCl, then homogenized in 2.5 ml of20 mMTris~HCl buffer (pH 7.5), enriched with 250 mM sucrose, with an Ultraturrax homogenizer (maximal speed for 5 sec) followed by ad~ dition of 12.5 ml of the same buffer, 7 up and down strokes with a glass-Teflon homogenizer, and filtration on 2 layers of medical gauze. The resulting homogenate was used immediately or stored in liquid nitrogen until use. The striatum was homogenized in 2 ml of 20 mM Tris-HCI buffer (pH 7.5) enriched with 250 mM sucrose, using a glass-Teflon homogenizer (7 up and down strokes). The resulting homogenate was stored in liquid nitrogen until use, and diluted 20-fold with the same buffer immediately before the experiment. The pancreas was minced with scissors, homogenized with a glass-Teflon homogenizer in 8 ml of 300 mM sucrose enriched with Trasylol (500 KIU/ml) and bacitracin (0.2 mg/ml). The resulting homogenate was immediately filtered on two layers of medical gauze and diluted 11-fold with an incubation buffer made of66 mM sodium phosphate (pH 7 .4), 2.6 mM MgC1 2 , 500 KIU/ml Trasylol, 0.2 mg/ml bacitracin, and 13 mg/ml bovine serum albumin.
Receptor-Binding Studies
Binding sturlies were performed at 25°C in a 50 mM sodium phosphate buffer (pH 7.4) enriched with 2 mM MgC1 2 and containing [
3 H]NMS and the indicated unlabelled drug concentrations in a total volume of 1.2 ml. For pancreas binding studies, the incubation buffer also contained bovine serum albumin (1% w/v), bacitracin (0.2 mg/ml), and Trasylol (500 KIU/ml) to prevent receptor degradation. 4 For incubation with rat heart homogenates, we used 80 JJ.l of the homogenate, corresponding to 400-500 J.l.g protein per assay. The 2-h incubation periodwas sufficient to allow equilibrium binding. We preincubated 80 JJ.l of the homogenate (equivalent to about 30 JJ.g protein) in a total volume of 1.2 ml in the presence of [ 3 H]NMS and unlabeled drugs. A 2-h preincubation period allowed equilibrium binding. We then added 1 ~ atropine and let tracer dissociation to proceed for 35 min before filtration. This procedure permitted us to investigate tracer binding to striatum M 4 ("B") receptors only. 4 • 8 The tracer concentration used in these experiments (0.25 nM) was equivalent to 5-fold the tracer's K 0 value at striatum M 4 receptors. 8 For incubation with rat pancreas homogenate, we added 980 JJ-l of homogenate to 220 ,...1 drug and tracer (in water). A 4-h incubation periodwas necessary to allow equilibrium binding.
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The [ 3 H]NMS concentration used was 0.24 nM, i.e., 2-fold the tracer's K 0 value at pancreas M 3 binding sites.
11 All incubations were terminated by addition of 2 ml of ice-cold filtration buffer (50 mM sodium phosphate buffer, pH 7.4). Bound and free tracer were immediately separated by filtration on GF/C glass-fiber filters (Whatman, Maidstone, England) presoaked overnight in 0.05% polyethyleneimine. The samples were rinsed three times with filtration buffer. The filters were then dried, and the bound radioactivity counted by liquid scintillation. Nonspecific Protein concentration was determined according to Lowry et al. 19 using bovine serum albumin as stan~ dard.
Analysis of Binding Data
All competition curves were repeated in duplicate, at least three times on different preparations. IC 50 values were determined by a computer~aided procedure, 20 The binding free energy (~G) for the formation of a ligand-receptor complex is related to its affinity constant Ka by Eq. (1):
!lG values were therefore calculated according to Eq. (2), using experimentally determined Ki values (K 8 =
Ki -1):
~G = -RT In l!K; RESULTS (2) As shown in Figures 3 and 4 , the four compounds investigated in this study inhibited [ 3 H]NM8 binding to the four muscarinic receptors in a manner consistent with competition for a single binding site (Hili coefficients were not significantly different from unity).
Tbe affinity oftbe hexahydro-difenidol eutomer, (R)· bexahydro-difenidol, for Mtt M 3 , and M 4 receptors was greater than its affinity for M 2 receptors. The hexahydro-difenidol distomer, (8)-bexahydro-difenidol, had a similar affinity for tbe four subtypes (Table 1, Figs. 3  and 4) . As a result, tbe eudismic index [(pKi (eutomer) -pKi (distomer)] at M 1 , M 3 , and M 4 receptors was greater tban tbat at M 2 receptors (Table 1) .
Difenidol and dicyclidol had lower affinities than (R)-bexabydro-difenidol and higber affinities than the (8)-enantiomer at tbe four subtypes (Table 1) . Difenidol bad a somewbat higher affinity for M 1 , M 3 , and M 4 sites as compared to M 2 sites (5-fold selectivity). By contrast, dicyclidol bad a lower affinity for M 2 and M 3 (as compared to M 1 and M 4 ) sites.
By contrast with our previous results with procyclidine, 15 tbe affinity Iosses due to replacement of tbe pbenyl ring by a cyclohexyl group and tbe cyclobexyl ring by a pbenyl moiety in (R)-hexahydrodifenidol were not fully additive. (8) "'''he pKi values of (R)-procyclidine, (S)-procyclidine, pyrrinol, and hexahydro-procyclidine found in a previous work 15 are shown for comparison.
W AELBROECK ET AL. ~arable, our results cannot be explained by contaminatlon of (8)-hexahydro-difenidol by the (R)-enantiomer. DISCUSSION We have previously shown that the stereoselective binding of the enantiomers of procyclidine to muscarinic binding sites is best explained by the existence of four subsites (Fig. 2) : one for the protonated amino group, one for the hydroxy group, one phenylpreferring hydrophobic subsite, and one cyclohexylpreferring hydrophobic subsite.t 5 The relative spatial positions of these four subsites is such that (R)-procyclidine has a greater affinity than (8)-procyclidine due to a better interaction of the hydrophobic groups with their corresponding subsites. The free energy of (R)-procyclidine binding can therefore be described by Eq. (3):
where ÄGtt ÄG 2 , 6.G 3 , and 6.G 4 represent the free energy achievable by an optimal interaction ofthe phenyl ring of the Iigand with receptor site 1, the cyclohexyl group with receptor site 2, the hydroxy group with receptor site 3, and the protonated amino group with rec~ptor site 4. tiG values should be as negative as possible to obtain high affinity binding, and factors cx, ß, -y, and 8 in Eq. (3) take into account the fact that all four groups are not of necessity simultaneously in the optimal positions to interact with receptor sites 1 to 4 (cx, ß, -y, and 8 values probably vary between 0 and 1, provided that the corresponding group does not obstruct binding by steric hindrance).
We compared in this work the binding properties of hexahydro-difenidol enantiomers and of two achiral analogues, difenidol and dicyclidol (Fig. 1) to four muscarinic receptor subtypes. Our results confirm that the presence of a phenyl and a cyclohexyl ring in the correct spatial position [(R)-configuration] is important for the binding ofhexahydro-difenidol to muscarinic receptors. lndeed, the affinity decrease due to replacement of the cyclohexyl ring by a phenyl group varied between 0.6 and 1.2 log units (corresponding to an increase of the binding free energy of0.8 to 1.6 kcal/mol) ( Table 2) . The affinity decrease due to replacement of the phenyl by a cyclohexyl ring was even more impressive. It amounted to 0.9 to 1.5log units (free energy difference: 1.2 to 2.6 kcal/mol) ( Table 2) .
The binding free energy decrease due to replacement of the phenyl and the cyclohexyl groups of (R)-hexahydro-difenidol by, respectively, a cyclohexyl and a phenyl moiety was additive in case of M 4 receptors ( Table 2) .
In contrast with our previous results, using the procyclidine enantiomers (Tables 1 and 2 ), t 5 this substitution effect was not fully additive at M 1 , M 2 , and M 3 receptors: the difference of the free energy of binding of (S)-and (R)-hexahydro-difenidol to Mt, M 2 , and M 3 subtypes was lower than expected by up to 1 kcal/mol. These discrepancies were subtype dependent and not correlated with receptor stereoselectivity, indicating bThe differences between the free energies of binding of (S)-procyclidine, pyninol, or hexahydro-procyclidine and (R)-procyclidine found in a previous work 16 are shown for comparison.
csum of the differences of the free energies of binding of (R).
hexahydro-difenidol and difenidol and of (R)-hexahydro-difenidol and d.icyclidol.
that they did not reflect an imperfect separation of the (R)-and (8)-enantiomers. They were small, when compared with the free energy of binding of the drugs: at most 12% of the binding free energy of the (8)-enantiomer to the receptors. We would like to suggest that by contrast with (R)-procyclidine, the four subgroups ofhexahydro-difenidol cannot be simultaneously in the optimal position to interact with the corresponding four subsites of muscarinic M 1 , M 2 , and M 3 receptors. This corresponds in Eq. (3) to values ofthe parameters cx, ß, -y, and 8 <1.0.
The results indicate that, when the structure of (R)-hexahydro-difenidol is modified, e.g., by replacement of the phenylring in subsite 1 by a cyclohexyl group <~ dicyclidol), the position of dicyclidol in the receptor is adjusted to increase the importance of the (good) interaction with subsites 2, 3, and 4 at the expense of the (~eakened) interaction with subsite 1. Therefore, the d1fference of the free energy of binding of (R)-hexahydro-difenidol and, for instance, difenidol or dicyclidol does not reflect exactly the modification of A.G 1 or 6.G 2 values. The development of an interaction model using molecular modeling methods and based on published Mt, M 2 , M 3 , and M 4 receptor protein sequences 23 might provide an improved rationale for the stereoselective interactions of (R)-and (8)-hexahydro-difenidol (this study), and of (R)-and (8)-procyclidinet5 with muscarinic receptor subtypes.
CONCLUSION
The muscarinic receptor stereoselectivity for the hexahydro-difenidol enantiomers is probably explained at least in part by weaker binding ofthe phenyl and cyclohexyl group of the (8)-isomer. The four (8)-hexahydro-difenidol binding moieties (phenyl, cyclohexyl, OH group, and protonated amino group), however, cannot simultaneously form optimal interactions with each of the corresponding four subsites of muscarinic receptors. The results indicate that the loss of binding affinity (increase of the free energy of binding) due to replacement ofthe phenyl and cyclohexyl groups was not fully additive when considering the M 1 , M 2 , and M 3 sites.
